NEW YORK, May 9, 2016 /PRNewswire/ -- BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, including its Phase III immuno-oncology compound and strong pipeline in collaboration with the Fred Hutchinson Cancer Research Center, today announced that its Chief Medical Officer, Ramon Mohanlal, M.D., Ph.D., will serve on a prominent panel at the 4th Annual Chief Medical Officer Summit to address tomorrow's challenges for CMOs. The panel will take place on Wednesday, May 11, 2016, at 8:45 a.m. ET in Boston, Mass.
"The healthcare industry is experiencing an era of change, and CMOs at emerging to mid-sized biopharmaceutical companies are accountable for driving the clinical development and CRO management while meeting the needs of investors and positioning for an appropriate exit," said Dr. Mohanlal. "This session will discuss important questions that CMOs are facing – from how clinical development is changing and whether or not we need Phase II trials to challenging new ways of developing drugs and how CMOs can create value for the company. We will touch on next steps for patient recruitment, as well."
Dr. Mohanlal has more than 20 years of global experience in strategic drug development at big pharma, biotechs and start-ups. His expertise includes clinical development of drugs in all phases (preclinical and I, II, III, IV clinical), regulatory filings and maintaining drugs on the market. He was the Clinical Head of Established Products, Oncology, for Novartis, where he managed a $2 billion portfolio of oncology drugs on the market. In addition, he developed immuno-oncology combination therapy programs with checkpoint inhibitors at AstraZeneca.
"BeyondSpring is pleased to participate in this panel and drive the discussion between CMOs and R&D executives to address the unique challenges that are associated with directing and managing all R&D functions with limited resources," added Lan Huang, Ph.D., Co-founder, Chairman and CEO, BeyondSpring Pharmaceuticals. "We want be part of this strong network of industry leaders to develop creative and valuable solutions to advance the creation of assets that will serve to advance medical care."
About BeyondSpring Pharmaceuticals
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative cancer therapies targeting immuno-oncology and tumor vascularization. BeyondSpring has advanced its lead asset, Plinabulin, into a Phase III clinical trial as a direct anticancer agent in non-small cell lung cancer. The Company is also planning a Phase III clinical trial for Plinabulin in the prevention of Docetaxel-induced Neutropenia. BeyondSpring's management team brought a combined 30+ drugs to market. The Company's immuno-oncology pipeline is robust, including a collaboration agreement with the Fred Hutchinson Cancer Research Center.
About Plinabulin
Plinabulin is a small molecule agent that is administered by IV infusion (30-minute infusion) and is administered 60 minutes after completion of Docetaxel infusion, on the same day of Docetaxel infusion.
CONTACT INFO:
Caitlin Kasunich / Katherine Swift
KCSA Strategic Communications
212.896.1241 / 646.280.8729
ckasunich@kcsa.com / kswift@kcsa.com
SOURCE BeyondSpring Pharmaceuticals